JO
CTIC

John Overdeck’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

John Overdeck’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-160,385
Closed -$964K – 3368
2022
Q4 		$964K Sell
160,385
-35,364
-18% -$193K ﹤0.01% 1713
2022
Q3 		$1.14M Sell
195,749
-1,203,623
-86% -$7.5M ﹤0.01% 1400
2022
Q2 		$8.35M Sell
1,399,372
-419,590
-23% -$2.15M 0.03% 572
2022
Q1 		$8.49M Buy
1,818,962
+1,464,744
+414% +$4.37M 0.03% 672
2021
Q4 		$878K Sell
354,218
-715,025
-67% -$1.75M ﹤0.01% 2678
2021
Q3 		$3.15M Sell
1,069,243
-202,576
-16% -$552K 0.01% 1571
2021
Q2 		$3.18M Buy
1,271,819
+572,907
+82% +$1.37M 0.01% 1503
2021
Q1 		$2.03M Buy
698,912
+283,758
+68% +$926K 0.01% 1696
2020
Q4 		$1.34M Buy
415,154
+239,474
+136% +$797K ﹤0.01% 1780
2020
Q3 		$378K Buy
175,680
+138,188
+369% +$176K ﹤0.01% 2438
2020
Q2 		$43K Sell
37,492
-1,600
-4% -$1.69K ﹤0.01% 2847
2020
Q1 		$36K Sell
39,092
-30,861
-44% -$35.4K ﹤0.01% 2951
2019
Q4 		$111K Sell
69,953
-37,503
-35% -$35.5K ﹤0.01% 3517
2019
Q3 		$90K Sell
107,456
-22,356
-17% -$17.1K ﹤0.01% 3319
2019
Q2 		$112K Sell
129,812
-45,302
-26% -$41.8K ﹤0.01% 3190
2019
Q1 		$170K Sell
175,114
-44,455
-20% -$46.8K ﹤0.01% 2843
2018
Q4 		$161K Buy
219,569
+10,759
+5% +$17.7K ﹤0.01% 2756
2018
Q3 		$451K Buy
208,810
+56,841
+37% +$141K ﹤0.01% 2524
2018
Q2 		$757K Buy
151,969
+71,700
+89% +$314K ﹤0.01% 2352
2018
Q1 		$313K Buy
+80,269
New +$282K ﹤0.01% 2754
2014
Q2 		– Sell
-9,741
Closed -$331K – 2561
2014
Q1 		$331K Buy
9,741
+3,526
+57% +$120K ﹤0.01% 1634
2013
Q4 		$120K Buy
+6,215
New +$113K ﹤0.01% 2073

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

John Overdeck's CTIC Position: Q1 2023 in Review

John Overdeck sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 160,385 shares — an estimated $964K sold.

John Overdeck first reported a position in CTIC in Q4 2013 and held it in 22 quarters. The position peaked at $8.49M in Q1 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • John Overdeck reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • John Overdeck sold 160,385 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $964K.
  • John Overdeck first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2013 and held it in 22 quarters.
  • John Overdeck's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.49M in Q1 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Two Sigma Investments's 13F filing for Q1 2023, filed 15 May 2023.